Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 3/20 | 0.59 |
| ▸ | HRH1 | P35367 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.56 |
| ▸ | HRH2 | P25021 | 2/20 | 0.56 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.56 |
| ▸ | HTR2B | P41595 | 2/20 | 0.56 |
| ▸ | MTOR | P42345 | 2/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9631337 | 0.89 | HRH1 (0.62) | SETD7HRH1TSHRALDH1A1ABCB11 | |
| SCHEMBL9850494 | 0.85 | HRH1 (0.76) | SETD7HRH1TSHRALDH1A1ABCB11 | |
| SCHEMBL2861991 | 0.83 | SETD7 (0.50) | SETD7HRH1TSHRALDH1A1ABCB11 | |
| SCHEMBL9718763 | 0.83 | SETD7 (0.63) | SETD7HRH1TSHRALDH1A1ABCB11 | |
| SCHEMBL9844364 | 0.83 | CHRM2 (0.57) | SETD7HRH1TSHRALDH1A1ABCB11 | |
| SCHEMBL9850666 | 0.82 | SETD7 (0.54) | SETD7HRH1TSHRALDH1A1ABCB11 | |
| SCHEMBL17416671 | 0.82 | HRH1 (0.43) | SETD7HRH1TSHRALDH1A1ABCB11 | |
| Hydrochloric Acid SCHEMBL9718750 | 0.81 | SETD7 (0.53) | SETD7HRH1TSHRALDH1A1ABCB11 | |
| SCHEMBL9718808 | 0.81 | SETD7 (0.60) | SETD7HRH1TSHRALDH1A1ABCB11 | |
| Hydrochloric Acid SCHEMBL9718722 | 0.80 | SETD7 (0.59) | SETD7HRH1TSHRALDH1A1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122260-A2 | INHIBITORS OF SARS-COV-2 | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230133974-A1 | HYBRIDOMA CELL LINE OF SECRETING CYPROHEPTADINE MONOCLONAL ANTIBODIES AND PREPARATION METHOD THEREOF | JIANGNAN UNIVERSITY (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230133974-A1 | HYBRIDOMA CELL LINE OF SECRETING CYPROHEPTADINE MONOCLONAL ANTIBODIES AND PREPARATION METHOD THEREOF | JIANGNAN UNIVERSITY (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20190284303-A1 | Hybridoma cell line of secreting cyproheptadine monoclonal antibodies and preparation method thereof | JIANGNAN UNIVERSITY | 2019-09-19 | — | — | US | disclosed |
| US-9493420-B2 | Quinoline derivatives and uses thereof | PORTLAND STATE UNIVERSITY (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493420-B2 | Quinoline derivatives and uses thereof | PORTLAND STATE UNIVERSITY (US) | 2016-11-15 | — | — | US | disclosed |
| US-9365553-B2 | Heterocyclic compound and H1 receptor antagonist | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| US-9365553-B2 | Heterocyclic compound and H1 receptor antagonist | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| EP-2578569-B1 | HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARM CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| US-20130310348-A1 | QUINOLINE DERIVATIVES AND USES THEREOF | STATE UNIVERSITY (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2011148888-A1 | HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST | あすか製薬株式会社 (JP) | 2011-12-01 | — | — | WO | disclosed |
| US-20110257160-A1 | QUINOLINE DERIVATIVES AND USES THEREOF | Board of Higher Education on behalf of Portland State University | 2011-10-20 | — | — | US | disclosed |
| US-20110257160-A1 | QUINOLINE DERIVATIVES AND USES THEREOF | Board of Higher Education on behalf of Portland State University | 2011-10-20 | — | — | US | disclosed |
| US-7968539-B2 | reversed chloroquines; to treat chloroquine resistant/sensitive malaria parasites; N'-(7-Chloro-quinolin-4-yl)-N-[3-(10,11-dihydro-dibenzo[b,f]azepin-5-yl)-propyl]-N-methyl-propane-1,3-diamine | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968539-B2 | reversed chloroquines; to treat chloroquine resistant/sensitive malaria parasites; N'-(7-Chloro-quinolin-4-yl)-N-[3-(10,11-dihydro-dibenzo[b,f]azepin-5-yl)-propyl]-N-methyl-propane-1,3-diamine | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) | 2011-06-28 | — | — | US | disclosed |
| US-20080188462-A1 | Quinoline Derivatives And Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-08-07 | — | — | US | disclosed |
| US-20080188462-A1 | Quinoline Derivatives And Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-08-07 | — | — | US | disclosed |
| WO-2000024715-A1 | PIPERIDINE COMPOUNDS AND THEIR USE IN THE POPULATION CONTROL OF RODENTS AND OTHER VERTEBRATE PESTS | ALMIRALL PRODESFARMA, S.A. (ES) | 2000-05-04 | — | — | WO | disclosed |
| US-5095022-A | Antiallergens | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1992-03-10 | — | — | US | disclosed |
| EP-0406739-A2 | Piperidine derivative, method for preparation thereof, and a pharmaceutical composition comprising the same | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1991-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310348-A1 | QUINOLINE DERIVATIVES AND USES THEREOF | RECQL, QARS1, QTRT1 | SETD7 2366/4885HRH1 547/4885TSHR 4448/4885 |
| US-20230133974-A1 | HYBRIDOMA CELL LINE OF SECRETING CYPROHEPTADINE MONOCLONAL ANTIBODIES AND PREPARATION METHOD THEREOF | HRH1, HRH2, HRH3 | SETD7 3560/4885HRH1 1/4885TSHR 1946/4885 |
| US-20110257160-A1 | QUINOLINE DERIVATIVES AND USES THEREOF | RECQL, QARS1, QTRT1 | SETD7 2366/4885HRH1 547/4885TSHR 4448/4885 |
| US-20080188462-A1 | Quinoline Derivatives And Uses Thereof | RECQL, QARS1, QTRT1 | SETD7 2366/4885HRH1 547/4885TSHR 4448/4885 |
| US-20190284303-A1 | Hybridoma cell line of secreting cyproheptadine monoclonal antibodies and preparation method thereof | HRH1, HRH2, HRH3 | SETD7 3560/4885HRH1 1/4885TSHR 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.